Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285011 | 0.88 | TSHR (0.43) | HTR1ADRD2DRD3RAB9AADORA3 | |
| SCHEMBL13459228 | 0.78 | AR (0.40) | HTR1ADRD2DRD3ADORA3ADORA2A | |
| SCHEMBL13459218 | 0.74 | ALDH3A1 (0.40) | CRHR1DPP4 | |
| SCHEMBL13459224 | 0.74 | DPP4 (0.44) | HTR1ADRD2DRD3CRHR1RAB9A | |
| SCHEMBL3284887 | 0.74 | CSNK2A2 (0.41) | CRHR1RAB9A | |
| SCHEMBL3293146 | 0.74 | UTS2R (0.41) | HTR1ADRD2DRD3RAB9ALMNA | |
| SCHEMBL3292254 | 0.74 | HSD17B10 (0.46) | HTR1ADRD2DRD3RAB9ALMNA | |
| SCHEMBL13015480 | 0.71 | DAO (0.66) | HTR1AADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2085302 | 0.71 | ADORA3 (0.41) | HTR1ADRD2DRD3ADORA3ADORA2A | |
| SCHEMBL3285641 | 0.71 | HTR1A (0.44) | HTR1ADRD2DRD3ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | HTR1A 123/4885DRD2 172/4885DRD3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.